COSTA MESA, Calif., June 1, 2026 — Veritas Aortic Solutions, the latest company to spin out of inQB8 Medical Technologies, is pleased to announce the closing of $12M in Seed financing to advance innovative solutions for the treatment of Root and Ascending Aortic Diseases. The funding round was led by a group of experienced MedTech angel investors with strong participation from Cedars-Sinai Intellectual Property Company along with inQB8’s existing investors. The funds will support the continued development of the Veritas Transcatheter Valved Aortic Root Conduit (TVARC) through First-in-Human clinical use. The Veritas TVARC is designed to offer a comprehensive, interventional, non-surgical treatment for high-risk Root and Ascending Aortic Diseases, including Dissections, Aneurysms, and other pathologies that specifically involve the aortic root, coronary ostia, and/or the ascending aorta.

As part of the financing, Chad Martinson (former Medtronic CoreValve executive and former CEO of ACOVA Integrated Health), Judd Nordquist (CEO of Ibis Scientific), and Nirdesh Gupta PhD (Managing Partner of Cedars-Sinai Intellectual Property Company (CSIPCo)), joined Veritas and inQB8 co-founders, Arshad Quadri, MD and J. Brent Ratz, on the company’s Board of Directors.

“With combined mortality and morbidity rates as high as 65%, it is hard to overstate the risk associated with current surgical treatments for acute conditions of the ascending aorta,” said Arshad Quadri MD, Co-Founder, Executive Chairman and Chief Medical Officer of Veritas Aortic Solutions. “As a cardiac surgeon myself, I have performed these procedures numerous times. They are complex, challenging, and highly invasive. Endovascular options for the descending aorta and the arch have been available for a long time, but open-heart surgery remains the only approved option for patients with root and ascending aortic pathologies. It has always been a dream of mine to be able to offer these patients a faster, safer, less-invasive option, and today we are one step closer to making that a reality.”

The Veritas TVARC system is a single permanent implant that combines a bioprosthetic aortic valve, ascending aortic graft, and the company’s proprietary Chameleon Eye™ coronary perfusion ports and is designed to seal-off the diseased or damaged part of the aorta and restore healthy blood flow to the coronaries and the rest of the body. The system includes a custom transfemoral delivery catheter that is intended to eliminate the need for open-heart surgery and allow for precise positioning and controlled deployment of the implant.

“The Veritas TVARC system represents the type of patient-centered innovation we seek to support at Cedars-Sinai,” said Nirdesh Gupta, PhD, Managing Partner of Cedars-Sinai Intellectual Property Company. “We are pleased to participate in this financing to help advance a novel endovascular approach to Aortic Root and Ascending Aortic Disease—an area where treatment options have remained largely unchanged for years despite significant patient risk. We believe this technology has the potential to meaningfully improve outcomes for patients facing life-threatening cardiovascular disease.”

“After establishing the Veritas program within inQB8 Medical Technologies and rapidly advancing it through prototyping, bench testing, and successful chronic animal studies, we are honored to have the support of seasoned MedTech investors, leading physicians, and a world-class healthcare organization like Cedars-Sinai to accelerate our development and bring this technology towards its first clinical application,” added J. Brent Ratz, Co-Founder and Chief Executive Officer of Veritas Aortic Solutions. “In our 20+ year partnership, Dr. Quadri and I have collaborated to create solutions for several cardiovascular issues. Given the complexity of Root and Ascending Aortic Diseases and the dire need for an interventional solution, I believe Veritas is poised to be the most meaningful of all in terms of patient impact.”

About Veritas Aortic Solutions
Veritas Aortic Solutions is a privately held medical device company committed to improving outcomes for patients with Aortic Disease. The company’s flagship technology, the Veritas Transcatheter Valved Aortic Root Conduit (TVARC) is a single permanent implant that combines a bioprosthetic aortic valve, ascending aortic graft, and the company’s proprietary Chameleon Eye™ coronary perfusion ports and is designed to seal-off the diseased or damaged part of the aorta and restore healthy blood flow to the coronaries and the rest of the body. Veritas was founded and incubated within inQB8 Medical Technologies, LLC and spun-out as a standalone company in late 2025 to provide a comprehensive solution to pathologies affecting the most critical areas of the heart, including the aortic root, coronaries and ascending aorta. www.veritasaortic.com

About Cedars-Sinai Intellectual Property Company (CSIPCo)
Cedars-Sinai Intellectual Property Company is the investment arm of Cedars-Sinai, focused on healthcare and life sciences startups across med tech (devices & diagnostics), biotech (drug discovery programs) and health tech (regulated digital health). CSIPCo invests in companies that strongly align with Cedars-Sinai Health System’s mission of advancing healthcare and improving patient outcomes.

About inQB8 Medical Technologies LLC
inQB8 Medical Technologies is a privately held medical device incubator with offices in Massachusetts and California co-founded by Dr. Arshad Quadri, MD, and J. Brent Ratz, MBA. inQB8 specializes in developing cutting-edge interventional solutions for major cardiovascular diseases, accelerating projects through prototyping, bench, and pre-clinical testing. Veritas is the fourth program to come out of the inQB8 team. Previous successes include CardiAQ Valve Technologies (Transcatheter Mitral Valve Replacement, acquired by Edwards Lifesciences in 2015), MonarQ (Transcatheter Tricuspid Valve Replacement, acquired by Peijia Medical in 2021), and Relief Cardiovascular (interventional Heart Failure management, formed in 2024 with Series A and FIH completed in 2025).

SOURCE Veritas Aortic Solutions

The Richmond office opens June 1, followed by a Chesapeake office July 1. Together, the locations establish Insurcomm’s footprint in Virginia and extend its 24/7 emergency response across both the Richmond metro and Hampton Roads. Customers can rely on Insurcomm for emergency response, remediation, reconstruction, and environmental services—all handled by one team that sees the job from start to finish.

“Virginia property owners and the carriers who serve them deserve a team they can count on when things don’t go as planned,” said Kelly Brewer, CEO of Insurcomm Restoration and Fortify Companies. “Opening in Richmond and Chesapeake lets us be closer, respond faster, and deliver the full set of capabilities people need—whether it’s a single property loss or a larger, more complex event. That’s what everything going right looks like.” 

Strengthening Regional Response and Support

Virginia properties face year-round risk, from Atlantic hurricanes and coastal storms to water intrusion, fire and smoke damage, and mold. With local teams now on the ground backed by national resources, Insurcomm can respond quickly, manage every stage of recovery under one roof, and maintain consistent service across the region when demand surges. Clients work with a single accountable team and a single point of contact from first notice of loss through final walkthrough, eliminating the handoffs and delays that characterize a typical restoration claim.

A Growing National Network

The Virginia offices are part of a broader, coordinated network built through Fortify Companies, bringing together local response capabilities with national scale. As part of the Fortify platform, Insurcomm connects prevention, emergency response, and reconstruction under one roof—helping reduce delays, improve visibility, and deliver a more seamless recovery experience from initial loss through long-term property care.

Need Emergency Restoration in Virginia?

For more information or to request emergency service, visit www.insurcomm.com or call (844) 424-9283.

About Insurcomm

Insurcomm delivers full-service restoration and emergency response you can count on when everything needs to go right across residential, commercial, and catastrophe response. For more than 30 years, we’ve helped property owners, facility teams, and communities recover from water, fire, mold, storm events, and environmental hazards.

We believe people deserve to know what’s happening, who’s handling it, and when it will be done, without surprises and without delays. From the first call to the final walkthrough, our mission is simple: You deserve everything going right, so we built a company that makes it happen.

To learn more about Insurcomm, visit our website or follow us on LinkedIn, Facebook, or Instagram.

About Fortify Companies 

Fortify Companies is building the nation’s most trusted property protection platform by uniting exceptional local teams across restoration, property services, and loss prevention under one operating standard. Faster response. Better outcomes. More resilient properties and communities. Learn more at fortifycompanies.com.

SOURCE Insurcomm Restoration

Capital Used to Finance Battery Storage and Solar Power Projects

SAN DIEGO, June 1, 2026 — Maxwell Power (“Maxwell”), formerly known as HDM Renewable Finance, today announced the successful closing of an investment commitment of $750 million from Fairtide Partners to finance battery storage and solar power projects. This investment increases Fairtide’s total commitment to more than $1 billion for projects developed by Maxwell.

Maxwell will use the investment to strengthen its position as a trusted partner to sales and installation companies that help consumers save money with advanced energy technologies. The capital also allows the Company to expand into new state markets where consumers experience structurally-high and rising energy costs. Retail electricity prices in Mid Atlantic, New England, and Pacific states increased 19% or more between 2022 and 2025, according to the US Department of Energy’s Energy Information Administration.

“Skyrocketing utility and gasoline costs are pinching everyone’s pocketbook,” said Dustin Dunaway, Maxwell’s Chief Revenue Officer. “Fairtide’s $1 billion commitment allows us to help more homeowners and businesses get affordable energy they can count on.”

Fairtide Partners cited Maxwell’s origination, underwriting, and management track record as the key catalysts for this additional capital commitment.

“We have worked with the Company’s leaders since 2010 and partnered with Maxwell since its founding in 2018,” said Nat Kreamer, Fairtide’s founder and lifetime chairman emeritus of the Solar Energy Industries Association (“SEIA”). “Maxwell has a great track record of delivering high-quality assets that create value for consumers and investors.”

About Maxwell Power

Homeowners and businesses are Powered for Life™ when they work with Maxwell. We are the power company that guarantees energy and savings to homeowners and small commercial customers. We deploy solar and battery storage systems to customers’ homes, monitor and maintain those systems, and ensure they deliver power. Our customers purchase power on long-term contracts that lock in savings. Since 2018, Maxwell has invested over $1 billion to help customers save an estimated $200 million. For more information about us please visit maxwellpower.com

About Fairtide Partners

Fairtide Partners makes infrastructure, tax equity, and private equity investments. The Firm has facilitated the financing of more than $1 billion battery storage and solar energy projects since 2018. Its private equity portfolio includes category-defining companies such as AMP for the waste industry and Highland for fleet vehicle electrification. Fairtide’s managing partners have over 40 years of combined experience as entrepreneurs, executives, investors, and industry-leading policy advocates. For more information about Fairtide please visit fairtidepartners.com

SOURCE Maxwell Power

And while technology has transformed nearly every aspect of retail, the commercial agreements that underpin the $18.8 trillion industry still rely heavily on spreadsheets, email chains, siloed systems, and informal ‘handshake’ agreements. 

Today, fewer than 50% of suppliers have written agreements with the retailers they sell to.

Handshake’s AI-powered platform gives retailers, wholesalers, and suppliers a single transparent system to make, track, and execute commercial agreements, replacing fragmented processes with a faster, more accountable, and data-driven way to manage deals.

The retail industry is already under immense pressure from inflation and cost volatility. Coupled with tighter margins, more complex supplier relationships, and increasingly scrutinised compliance, the need for efficient, scalable deal-making has never been greater.

By seamlessly unifying all commercial agreements in one platform, Handshake strengthens partnerships and empowers retail leaders to drive more effective change across their large trading teams.

Victor Angline, Director of Merchandising Strategy and Supplier Relations at Gopuff, says: “At Gopuff, our merchandising teams oversee hundreds of supplier partnerships across multiple categories, so it’s important we have the right tools to manage all the details. We chose Handshake to empower our merchants with a platform that enables seamless management of contracts, agreements, and joint business plans. They have been amazing partners, and we look forward to continued collaboration.” 

“Technology has transformed almost every corner of retail over the past decade, but retail buying still runs largely on spreadsheets, disconnected systems, and anecdotal memory,” says Alex Lindsay, co-founder and CEO of Handshake.

“That creates enormous operational complexity in an industry where margins are tight and every commercial decision matters. We believe there’s a huge opportunity to build the AI-native operating system for retail buying, one that gives retailers and suppliers the visibility, structure, and accountability they need to work better together.”

This funding will accelerate Handshake’s product development, expand its engineering and customer success teams, and support deeper partnerships with leading retailers and suppliers.

Peter Welch, co-founder and CTO of Handshake, adds: “Retail buying is a brutally tough job, and the sector faces structural headwinds that show no signs of easing. The commercial teams at the heart of it deserve better tools, visibility, and outcomes, which is why we built Handshake.

Handshake is a fundamental reimagining of how retailers and suppliers work together, and there’s never been a better moment to bring this to the sector. We believe this category is one of the largest untapped opportunities in retail.”

Delivering on this vision requires more than modern software. It requires deep retail expertise combined with world-class AI and product engineering. Handshake’s team brings together experience across retail operations, enterprise technology, and AI product development to build an operating system designed specifically for the realities of modern commerce.

And if Handshake gets this right, it won’t just modernise retail buying, it will help the entire industry deliver better value to millions of customers.

“Handshake is transforming how retailers and suppliers work together, and its team combines the technical depth and category expertise this problem demands. This is a category ripe for disruption in the age of AI,” says Cameron Ramsay, Director at Future Back Ventures by Bain & Company.

“Handshake’s platform offers a genuinely credible path forward on a problem the entire sector has wrestled with for years. And our Bain experience only reinforced our conviction in both the team and opportunity. Its potential to unlock value across retailers, wholesalers, and suppliers is substantial.” 

To learn more about Handshake, visit handshake-solutions.com or reach out to [email protected]. 

About Handshake

Handshake is the first AI-powered agreement platform built for retail. Designed to help retailers, wholesalers, and suppliers make, track, and execute commercial agreements in one transparent system, Handshake reduces operational complexity, improves commercial decision-making, and empowers leaders to drive effective change.

Founded in 2024 and headquartered in London, Handshake is backed by Triple Point Ventures, Future Back Ventures by Bain & Company, and Octopus Ventures. To learn more, visit handshake-solutions.com.

Photo – https://mma.prnewswire.com/media/2990950/Handshake.jpg
Logo – https://mma.prnewswire.com/media/2990949/5994520/Handshake_Logo.jpg

SOURCE Handshake Solutions Ltd

Cette nomination renforce la présence de TGV aux États-Unis et lui permet de se concentrer sur la région de la baie de San Francisco

SAN FRANCISCO et SINGAPOUR, 29 mai 2026 — True Global Ventures (TGV), société mondiale de capital-risque investissant dans des fondateurs visionnaires qui créent des entreprises technologiques de premier plan dans le domaine de l’IA, annonce aujourd’hui la nomination de Tal Elyashiv en tant que general partner.

Entrepreneur chevronné, investisseur en capital-risque et cadre dans le secteur des technologies, Elyashiv a mené une brillante carrière dans la Silicon Valley, à Wall Street et à Tel Aviv. Il apporte à l’entreprise une combinaison rare d’expertise en investissement dans les technologies de pointe, d’expérience en tant qu’opérateur et de leadership dans le domaine de la finance institutionnelle. Il s’installera aux États-Unis dans le courant de l’année, renforçant ainsi la présence croissante de TGV dans la région de la baie de San Francisco.

Israélien d’origine américaine ayant des racines dans deux des principaux écosystèmes d’innovation du monde, Elyashiv a passé des décennies à l’intersection de la technologie, des services financiers et du capital-risque.

Elyashiv est cofondateur et managing partner de SPiCE VC, le premier fonds de capital-risque entièrement tokenisé au monde. SPiCE VC est également reconnu comme un fonds de capital-risque très performant, avec de solides distributions par rapport au capital versé et une valeur totale par rapport au capital versé, surpassant de manière significative les indices de référence du secteur. Elyashiv poursuivra ses fonctions de direction au sein de SPiCE VC (actuellement dans sa phase finale de conversion de ses investissements) parallèlement à sa contribution à TGV.  Les mandats des fonds sont substantiellement différents et les deux fonctions ne présentent pas de conflit d’intérêt.

Outre son rôle de pionnier au sein de SPiCE VC, Elyashiv est également cofondateur de Securitize, qui est aujourd’hui la principale plateforme de tokenisation des actifs du monde réel à l’échelle mondiale et une entreprise déterminante dans le domaine des titres numériques. Il est également l’auteur de deux livres à succès, Blockchain Prophecies et l’ouvrage récemment publié Investing in Revolutions: Creating Wealth from Transformational Technology Waves, faisant de lui l’un des principaux leaders d’opinion sur la convergence de l’IA, de la blockchain et de l’informatique quantique.

Dans le domaine de la finance institutionnelle, il a été cadre supérieur chez Capital One et Bank of America, directeur de l’exploitation chez BondDesk Group, où il a dirigé le redressement majeur de la technologie et de la prestation de services, et directeur technique et responsable des nouvelles activités chez 888.

La nomination d’Elyashiv intervient alors que TGV continue d’accélérer sa focalisation sur les applications commerciales fondées sur l’IA par le biais du TGV Fund 6, qui dirige les investissements aux stades de l’amorçage tardif et de la série A, en mettant l’accent sur les startups basées en Californie.

« Tal apporte l’expérience de la gestion de fonds d’une société de capital-risque performante que nous recherchons chez TGV – en plus de cela, une personne qui a créé des entreprises, dirigé des institutions et investi avec conviction à travers de multiples cycles technologiques. Ses racines américaines et israéliennes lui confèrent une vision véritablement mondiale, et son retour aux États-Unis s’inscrit parfaitement dans le cadre de l’accent mis par TGV sur la région de la baie de San Francisco. Nous sommes ravis de l’accueillir dans notre équipe »
– Dušan Stojanović, managing partner, True Global Ventures

« TGV a construit quelque chose de rare – un fonds véritablement mondial avec le réseau, le portefeuille et la conviction de soutenir des fondateurs qui définissent des catégories aux stades les plus critiques de leur croissance. Après des décennies de construction à la frontière de la fintech et de la blockchain, je suis ravi de rejoindre une équipe qui partage ma conviction que l’IA et la blockchain sont les thèmes d’investissement déterminants de notre époque. Je me réjouis à la perspective de mettre mon expérience au service de True Global Ventures et de sa prochaine phase de croissance »
– Tal Elyashiv, general partner, True Global Ventures, managing partner, SPiCE VC

« La combinaison de Tal en tant qu’investisseur en capital-risque chevronné, opérateur prospère, dirigeant d’entreprise et expérience en matière de redressement est exceptionnelle. Il n’a pas seulement investi dans les domaines d’avant-garde, il les a construits. La profondeur et l’étendue de l’expertise de Tal et son exécution pratique seront un atout pour TGV et les entreprises de notre portefeuille au fur et à mesure qu’elles se développent. »
– Beatrice Lion, general partner, True Global Ventures

À PROPOS DE TRUE GLOBAL VENTURES
True Global Ventures (TGV) est une société mondiale de capital-risque qui investit dans des entreprises d’IA en phase de démarrage. Le portefeuille actuel de TGV comprend Prezent, Cynch, COVU, Obligo, Ledger, Animoca Brands, Jus Mundi, Coding Giants et bien d’autres. Presque toutes les sociétés de portefeuille se trouvent aux États-Unis ou entrent sur ce marché. Avec une présence à San Francisco, New York, Paris, Londres, Stockholm, Dubaï, Singapour et Hong Kong, TGV soutient les fondateurs visionnaires qui construisent la prochaine génération d’entreprises technologiques transformatrices. www.trueglobalventures.com

Photo – https://mma.prnewswire.com/media/2989447/1.jpg

Ernennung stärkt die US-Präsenz mit vertieftem Fokus von TGV auf die Bay Area

SAN FRANCISCO und SINGAPUR, 29. Mai 2026 — True Global Ventures (TGV), ein globales Risikokapitalunternehmen, das in visionäre Gründer investiert, die kategoriedefinierende KI-First-Technologieunternehmen aufbauen, gab heute die Ernennung von Tal Elyashiv zum General Partner bekannt.

Als erfahrener Unternehmer, Risikokapitalgeber und Führungskraft im Technologiebereich mit einer herausragenden Karriere im Silicon Valley, an der Wall Street und in Tel Aviv bringt Elyashiv eine seltene Kombination aus fundiertem Fachwissen im Bereich der Technologieinvestitionen, Erfahrung als Unternehmer und Führungsqualitäten im institutionellen Finanzwesen in das Unternehmen ein. Er wird noch in diesem Jahr in die USA umziehen und damit die wachsende Präsenz des TGV in der San Francisco Bay Area weiter verstärken.

Als amerikanischer Israeli mit Wurzeln in zwei der wichtigsten Innovationsökosysteme der Welt hat Elyashiv Jahrzehnte an der Schnittstelle von Technologie, Finanzdienstleistungen und Risikokapital verbracht.

Elyashiv ist Mitbegründer und Managing Partner von SPiCE VC, dem weltweit ersten vollständig tokenisierten Risikokapitalfonds. SPiCE VC ist auch als ein VC-Fonds mit Spitzenleistungen anerkannt, mit starken Ausschüttungen im Verhältnis zum eingezahlten Kapital (DPI) und dem Gesamtwert im Verhältnis zum eingezahlten Kapital (TVPI), die die Benchmarks der Branche deutlich übertreffen. Elyashiv wird seine Führungsrolle bei SPiCE VC (das sich derzeit in der Spätphase befindet) parallel zu seinem Beitrag bei TGV fortsetzen.  Die Mandate der Fonds sind sehr unterschiedlich und es besteht kein Interessenkonflikt zwischen den beiden Funktionen.

Neben seiner bahnbrechenden Führungsrolle bei SPiCE VC ist Elyashiv auch Mitbegründer von Securitize, der heute weltweit führenden Plattform für die Tokenisierung von realen Vermögenswerten und ein wegweisendes Unternehmen im Bereich der digitalen Wertpapiere. Er ist auch der Autor von zwei Bestsellern, Blockchain Prophecies und dem kürzlich veröffentlichten Investing in Revolutions: Creating Wealth from Transformational Technology Waves, wodurch er sich als einer der führenden Vordenker im Bereich der Konvergenz von KI, Blockchain und Quantencomputing etabliert hat.

Zu seinen früheren Funktionen im institutionellen Finanzwesen gehören die leitende Position bei Capital One und der Bank of America, die Position des Betriebsleiters bei der BondDesk Group, wo er den großen Turnaround der Technologie- und Servicebereitstellung leitete, sowie die Position des Technischen Leiters und Leiter für neue Geschäfte bei 888.

Die Ernennung von Elyashiv erfolgt zu einem Zeitpunkt, an dem TGV seinen Fokus auf KI-basierte Geschäftsanwendungen durch den TGV Fund 6 weiter verstärkt, der Investitionen in der späten Seed- und Series-A-Phase mit einem starken Fokus auf kalifornische Startups tätigt.

„Tal bringt die Erfahrung im Fondsmanagement eines erfolgreichen VCs mit, die wir bei TGV suchen – und darüber hinaus hat er über mehrere Technologiezyklen hinweg Unternehmen aufgebaut, Institutionen geleitet und mit Überzeugung investiert. Seine amerikanischen und israelischen Wurzeln verleihen ihm einen wahrhaft globalen Blickwinkel, und seine Rückkehr in die USA passt perfekt zum verstärktem Fokus von TGV auf die Bay Area. Wir freuen uns sehr, ihn in unserer Partnerschaft begrüßen zu dürfen.”
– Dušan Stojanović, Managing Partner, True Global Ventures

„TGV hat etwas Seltenes aufgebaut – einen wirklich globalen Fonds mit dem Netzwerk, dem Portfolio und der Überzeugung, kategorieprägende Gründer in den kritischsten Phasen ihres Wachstums zu unterstützen. Nachdem ich jahrzehntelang an der Grenze von Fintech und Blockchain gearbeitet habe, freue ich mich, einem Team beizutreten, das meine Überzeugung teilt, dass KI und Blockchain die entscheidenden Anlagethemen unserer Zeit sind. Ich freue mich darauf, meine Erfahrung in die Unterstützung von True Global Ventures und dessen nächstes Kapitel einzubringen.”
– Tal Elyashiv, General Partner, True Global Ventures, Managing Partner, SPiCE VC

„Tal bringt eine außergewöhnliche Kombination aus erfahrenem Risikokapitalgeber, erfolgreichem Betreiber, Unternehmensführung und Turnaround-Erfahrung. Er hat nicht nur an der Grenze investiert – er hat dort gebaut. Das umfassende und breit gefächerte Fachwissen von Tal und seine praktische Erfahrung werden für TGV und unsere Portfoliounternehmen bei ihrer Expansion von großem Nutzen sein.”
 – Beatrice Lion, General Partner, True Global Ventures

INFORMATIONEN ZU TRUE GLOBAL VENTURES
True Global Ventures (TGV) ist ein globales Risikokapitalunternehmen, das in der Frühphase in Unternehmen investiert, die auf KI spezialisiert sind. Zum aktuellen Portfolio von TGV gehören Prezent, Cynch, COVU, Obligo, Ledger, Animoca Brands, Jus Mundi, Coding Giants und viele andere. Fast alle Portfoliounternehmen befinden sich in den USA oder gehen in die USA. Mit Niederlassungen in San Francisco, New York, Paris, London, Stockholm, Dubai, Singapur und Hongkong unterstützt TGV visionäre Gründer, die die nächste Generation von transformativen Technologieunternehmen aufbauen. www.trueglobalventures.com

Foto – https://mma.prnewswire.com/media/2989447/1.jpg

The European approval lands alongside SHINE’s expansion into diagnostic radiopharmaceuticals. In January, the company acquired an established U.S. isotope manufacturing and distribution facility and product portfolio, adding decades of operational scale across diagnostic isotopes — Tc-99m generators, cardiac and neuroimaging agents, and Xe-133 for pulmonary imaging — used in millions of procedures each year. The combination gives hospitals, imaging centers, and radiopharmaceutical developers a single U.S.-based supplier across a wide spectrum of nuclear medicine.¹

“For years, our customers have asked for a reliable partner that can deliver both the diagnostic and therapeutic side of nuclear medicine,” said Michael Rossi, CEO of SHINE SPECT LLC. “EMA approval opens the door for SHINE’s radioisotope Lu-177 to be used in developing radioligand therapies at scale, and ultimately support the expanded reach of nuclear medicine to patients. Combined with the isotope manufacturing and distribution operation we run for North American hospitals and imaging centers, SHINE now serves both sides of nuclear medicine.”

A U.S. Production Platform Built for Reliability and Scale

SHINE produces Ilumira at its Cassiopeia facility in Janesville, Wisconsin, one of North America’s largest n.c.a. Lu-177 production sites, using a proprietary process. The facility provides commercial-scale supply for the global radiopharmaceutical market, with the ability to adjust capacity according to demand for approved Lu-177 therapies.

Ilumira is produced under cGMP and meets European Pharmacopeia standards. As a non-carrier-added product, Ilumira achieves ≥99.9% radionuclidic purity and high specific activity, characteristics that distinguish n.c.a. Lu-177 from carrier-added alternatives.^2,3 SHINE is one of the few lutetium producers that also recycles ytterbium (Yb-176), the starter material for all n.c.a. Lu-177. The result is less waste, improved efficiency, and a domestic supply chain radiopharmaceutical developers can plan around.

A New Era for Nuclear Medicine

The EMA approval is the latest in a series of major moves expanding SHINE’s nuclear medicine platform:

• SHINE acquired an established U.S. isotope manufacturing and distribution operation in January, expanding into diagnostic radiopharmaceuticals and adding immediate operational scale to its nuclear medicine platform
• The company closed a $240 million Series E led by Dr. Patrick Soon-Shiong in February. The investment included a strategic partnership with NantWorks featuring priority access to SHINE’s Lu-177 supply, positioning both companies to advance the next generation of targeted cancer treatment.
• SHINE received a $263 million conditional loan commitment from the U.S. Department of Energy in April to complete Chrysalis, designed to become the largest medical isotope production site in the world. The fusion-fission hybrid facility will produce molybdenum-99 — the parent isotope of the Tc-99m used in SHINE’s SPECT products — connecting the company’s isotope production to its diagnostic manufacturing under one supply chain.
• SHINE has also expanded its global distribution partnerships and built out its senior leadership team to support its next stage of growth.

With its integrated platform now spanning diagnostic and therapeutic radioisotopes from U.S. production, SHINE continues to scale capacity and expand global reach.

About Ilumira

Lu-177 is one of the most widely used isotopes in targeted cancer therapy. Paired with a targeting ligand, it delivers potent radiation to tumor cells while sparing healthy tissue.  Lu-177 is currently used as the nuclear isotope precursor in several radiopharmaceuticals that have approved and investigational uses across prostate cancer and neuroendocrine tumors, and a growing list of indications.²

Global demand for Lu-177 is soaring, but supply has been unstable, and most Lu-177 produced today is carrier-added, with lower radionuclidic purity.^2,3 Carrier-added Lu-177 contains non-therapeutic lutetium isotopes alongside the active material. Non-carrier-added Lu-177 separates them out for higher radionuclidic purity and a more concentrated source of active material.^2,3

Note: Ilumira is a radiopharmaceutical precursor, not a finished drug. It is solely intended for radiolabeling of carrier molecules and is not for direct patient use.

References:

[1] World Nuclear Association. Radioisotopes in medicine. Updated January 21, 2026. Accessed April 10, 2026. https://world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine

[2] Niu T, Fan M, Lin B, et al. Current clinical application of lutetium-177 in solid tumors (Review). Exp Ther Med. 2024;27(5):225. doi:10.3892/etm.2024.12514. PMID: 38596660; PMCID: PMC11002837. Accessed April 30, 2026.  https://pmc.ncbi.nlm.nih.gov/articles/PMC11002837/

[3] Dash A, Pillai MRA, Knapp FF Jr. Production of ^177Lu for Targeted Radionuclide Therapy: Available Options. Nucl Med Mol Imaging. 2015;49(2):85–107. Available from: PubMed Central. Accessed April 10, 2026

About SHINE

Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility.

SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy.

Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries. Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors.

Learn more at www.shinefusion.com.

SOURCE SHINE Technologies, LLC

De benoeming versterkt de aanwezigheid van de VS met de verdiepende focus van TGV in de Bay Area

SAN FRANCISCO en SINGAPORE, 29 mei 2026 — True Global Ventures (TGV), een wereldwijd durfkapitaalbedrijf dat investeert in visionaire oprichters die categorie-definiërende AI-first technologiebedrijven bouwen, kondigde vandaag de benoeming aan van Tal Elyashiv als Algemeen Partner.

Elyashiv, een ervaren ondernemer, venture capitalist en technologie-executive met een vooraanstaande carrière in Silicon Valley, Wall Street en Tel Aviv, brengt een zeldzame combinatie van deeptech-investeringsexpertise, ervaring als ondernemer en institutionele financieel leiderschap naar het bedrijf. Hij zal later dit jaar naar de VS verhuizen, waardoor de groeiende aanwezigheid van TGV in het San Francisco Bay Area verder wordt versterkt.

Elyashiv, een Amerikaans-Israëlische ondernemer met wortels in twee van ‘s werelds belangrijkste innovatie-ecosystemen, is al tientallen jaren actief op het snijvlak van technologie, financiële diensten en durfkapitaal.

Elyashiv is medeoprichter en managing partner van SPiCE VC, het eerste volledig getokeniseerde durfkapitaalfonds wereldwijd. SPiCE VC wordt ook erkend als een best presterend VC-fonds, met sterke distributies versus betaald kapitaal (DPI) en totale waarde versus betaald kapitaal (TVPI), die aanzienlijk beter presteren dan de benchmarks in de industrie. Elyashiv zal zijn leiderschap bij SPiCE VC (momenteel in de late oogstfase) parallel aan zijn bijdrage bij TGV voortzetten. De mandaten van de fondsen verschillen aanzienlijk en er bestaat geen belangenconflict tussen de twee rollen.

Naast zijn baanbrekende leiderschap bij SPiCE VC is Elyashiv ook medeoprichter van Securitize, nu het toonaangevende platform voor de tokenisatie van reële activa wereldwijd en een bepalend bedrijf in de digitale effectenruimte. Hij is ook de auteur van twee bestsellers, Blockchain Prophecies en het onlangs gepubliceerde Investing in Revolutions: Creating Wealth from Transformational Technology Waves, waardoor hij zich vestigt als een van de belangrijkste denkers op het gebied van de convergentie van AI, blockchain en kwantumcomputing.

Zijn eerdere rollen in institutionele financiering omvatten het dienen als senior executive bij Capital One en Bank of America, COO bij BondDesk Group, waar hij de grote ommekeer van technologie en dienstverlening leidde, en als CTO en hoofd van New Businesses bij 888.

De benoeming van Elyashiv komt omdat TGV zijn focus op AI-first zakelijke toepassingen blijft versnellen via TGV Fund 6, dat investeringen leidt in de late seed- en Series A-stadia met een sterke nadruk op in Californië gevestigde startups.

“Tal brengt de fund management-ervaring van een goed presterende VC die we bij TGV zoeken, bovenop iemand die bedrijven heeft opgebouwd, instellingen heeft geleid en met overtuiging heeft geïnvesteerd in meerdere technologische cycli. Zijn Amerikaanse en Israëlische wortels geven hem een echt wereldwijde zienswijze en zijn terugkeer naar de VS sluit perfect aan bij de verdiepende focus van TGV op de Bay Area. Wij zijn verheugd hem in het partnerschap te verwelkomen.”
— Dušan Stojanović, Managing Partner, True Global Ventures

“TGV heeft iets zeldzaams opgebouwd – een echt wereldwijd fonds met het netwerk, de portefeuille en de overtuiging om categorie-definiërende oprichters te ondersteunen in de meest cruciale stadia van hun groei. Na tientallen jaren te hebben gebouwd aan de grens van fintech en blockchain, ben ik verheugd om me aan te sluiten bij een team dat mijn overtuiging deelt dat AI en blockchain de bepalende investeringsthema’s van ons tijdperk zijn. Ik kijk ernaar uit om mijn ervaring in te zetten ter ondersteuning van True Global Ventures en de volgende fase van het bedrijf.”
— Tal Elyashiv, General Partner, True Global Ventures, Managing Partner, SPiCE VC

“Tal beschikt over een uitzonderlijke combinatie van ervaring als doorgewinterde durfkapitalist, succesvol ondernemer, ondernemer en specialist in het herstructureren van bedrijven.” Hij heeft daar niet alleen geïnvesteerd , maar ook iets opgebouwd. “De diepgaande en brede expertise van Tal en zijn praktische aanpak zullen een aanwinst zijn voor TGV en de bedrijven in onze portefeuille naarmate deze verder groeien.”
— Beatrice Lion, General Partner, True Global Ventures

OVER TRUE GLOBAL VENTURES
True Global Ventures (TGV) is een wereldwijd durfkapitaalbedrijf dat in een vroeg stadium investeert in AI-first bedrijven na de inkomsten. De huidige portfolio van TGV omvat Prezent, Cynch, COVU, Obligo, Ledger, Animoca Brands, Jus Mundi, Coding Giants en vele andere. Bijna alle portefeuillebedrijven zijn in de VS of komen de VS binnen. Met aanwezigheid in San Francisco, New York, Parijs, Londen, Stockholm, Dubai, Singapore en Hong Kong ondersteunt TGV visionaire oprichters die de volgende generatie van transformatieve technologie-ondernemingen bouwen. www.trueglobalventures.com

Foto – https://mma.prnewswire.com/media/2989447/1.jpg

SHANGHAI, May 29, 2026 — Forbes has released its 2026 Midas List, the definitive ranking of the world’s top venture capital investors. Alex Zhou, Managing Partner at Qiming Venture Partners, debuts at No. 80, recognizing his track record as a leading China-based investor focused on technology and artificial intelligence.

Known as the “Oscars of venture capital,” the Midas List is the most prestigious benchmark in global venture capital. The 2026 list marks its 25th anniversary, with intensified competition across the industry. Surging valuations for frontier companies including SpaceX, OpenAI and Anthropic have brought 25 new entrants to this year’s ranking.

Alex Zhou joined Qiming Venture Partners in 2014 and was promoted to Managing Partner in May 2024. He brings over 20 years of combined operational, entrepreneurial and investment experience, with a long-term focus on frontier technologies. He is one of the most active investors backing transformative AI and robotics startups globally.

Alex Zhou has delivered strong exit momentum in 2026. In the first five months of the year, four of his portfolio companies — Biren Technology, Zhipu AI, Axera Semiconductor and Viewtrix Technology — have completed public listings.

Alex Zhou adopts a pragmatic “half-step ahead” investment approach for tech and AI. Within his core areas of expertise, he identifies early industry inflection points and builds positions ahead of mainstream trends, avoiding speculative market hype. This forward-looking strategy has enabled him to capture outsized returns amid major technological paradigm shifts.

In late 2019, when China’s domestic GPU ecosystem remained immature and AI computing power was yet to gain widespread market recognition, Alex Zhou invested in Biren Technology at its founding. He led the company’s seed round and continued to support subsequent financings, helping the firm grow into the first Hong Kong-listed GPU company.

Alex Zhou made another early, high-impact bet on foundational AI in early 2022. At the time, large language models were still an emerging technology, and few investors recognized their commercial potential. His investment in Zhipu AI supported the development of the company’s first-generation GLM model, laying the foundation for its core technology development.

Alex Zhou’s early-stage focus also extends to embodied intelligence. He backed UBTECH Robotics eleven years ago and, in the current wave of embodied AI development, has led investments in a new batch of full-stack robotics companies integrating models and hardware, including TARS, Dexmal, GalaxyBot and ACE Robotics.

Founded in 2006, Qiming Venture Partners manages 11 USD funds and seven RMB funds, with $9.5 billion in assets under management. The firm focuses on two core pillars — technology and healthcare — forming a stable dual-driven investment strategy.

Qiming Venture Partners has maintained a long-term AI investment layout for over a decade. Starting with deep learning-focused investments in 2013, the firm has deployed more than RMB 12 billion into over 100 AI projects across the full industrial value chain, establishing itself as one of the most active and influential AI investors in China and Asia. The firm’s investment roadmap follows technological evolution across LLMs, multimodal AI and embodied intelligence, rather than short-term market trends.

In healthcare, Qiming Venture Partners is one of China’s earliest institutional investors dedicated to the sector. Over the past two decades, its healthcare team has invested in nearly 200 companies covering innovative pharmaceuticals, innovative medical devices, AI healthcare applications and other related areas. Its continuous investment has driven innovation in China’s life sciences industry and delivered practical clinical value globally.

Qiming Venture Partners’ technology and healthcare practices complement and empower one another. The firm’s healthcare industry expertise supports its judgments on AI+ healthcare applications opportunities, while its frontier tech insights help identify disruptive technology-driven healthcare startups. This cross-sector synergy forms Qiming Venture Partners’ key institutional advantage.

Qiming Venture Partners’ recurring recognition on the Midas List across technology, healthcare and AI reflects its long-built institutional capabilities: consistent focus on core sectors, proactive early deployment, and full-cycle investment expertise covering early to growth-stage companies.

Across both core verticals, Qiming Venture Partners executes systematic layout years before market consensus emerges, partnering with founders for long-term growth and achieving steady exit results. 

“For the next two decades, AI will stand as the most certain investment opportunity in China’s venture landscape,” said Duane Kuang, Founding Managing Partner of Qiming Venture Partners. The firm’s healthy cycle of fundraising, investment, portfolio management and exits continues to validate this long-term judgment.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine,  AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.